CLEAR HIV Trial
Phase 2
121
about 5 years
40+
3 sites in CA, TX
Why this study is shown
What this study is about
Researchers are testing whether Bempedoic acid, a medication, can lower cholesterol and inflammation in people with HIV who have heart disease or risk factors for it. The trial will last 1827 days and involve approximately 121 participants.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Placebo
- 2.Take Bempedoic acid
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
bempedoic acid
oral (Oral Tablet)
Secondary: Hb A1c Endpoint, IL-6 Endpoint, Triglycerides Endpoint
Cardiology / Heart, Immune, Infectious